TY - JOUR. T1 - Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by α-catenin. AU - Govindarajan, Rajgopal. AU - Zhao, Sumin. AU - Song, Xiao Hong. AU - Guo, Rong Jun. AU - Wheelock, Margaret. AU - Johnson, Keith R.. AU - Mehta, Parmender P. PY - 2002/12/20. Y1 - 2002/12/20. N2 - Gap junctions, composed of connexins, provide a pathway of direct intercellular communication for the diffusion of small molecules between cells. Evidence suggests that connexins act as tumor suppressors. We showed previously that expression of connexin-43 and connexin-32 in an indolent prostate cancer cell line, LNCaP, resulted in gap junction formation and growth inhibition. To elucidate the role of connexins in the progression of prostate cancer from a hormone-dependent to -independent state, we introduced connexin-43 and connexin-32 into an invasive, androgen-independent cell line, PC-3. Expression of these proteins in PC-3 cells resulted in intracellular ...
TY - JOUR. T1 - C16 and C17-heterocycle bearing androstanes. CYP17 inhibition studies and multiple effects on prostate cancer cells. AU - Moreira, V.M.. AU - Salvador, J. A. R.. AU - Matos Beja, A.. AU - Paixão, José A.. AU - Vasaitis, T. S.. AU - Njar, V. C. O.. PY - 2011/9/24. Y1 - 2011/9/24. N2 - Heterocycles are important features of biologically active molecules. Pyrrole, pyrimidine, indole, quinoline and purine are a few classes of heterocycles which have served as platforms for developing pharmaceutical agents for various applications (1). Many important naturally occurring steroids contain one or more heterocyclic ring(s), fused or attached to ring D, formed by modifications of the side chain (2). Moreover, attachment of heterocyclic moieties at diverse positions of the steroid core has provided novel compounds with a diverse range of biological activities including inhibition of cytochrome 17α-hydroxylase-C 17,20 -lyase (CYP17), one of the enzymes involved in androgen biosynthesis in ...
CyberKnife approved to treat prostate cancer at ETMC Cancer Institute - CyberKnife approved to treat prostate cancer at ETMC Cancer Institute The East Texas Medical Center Cancer Institute is the only cancer center in the region to offer the Cyber...
TY - JOUR. T1 - Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. AU - Tumati, Vasu. AU - Mathur, Sanjeev. AU - Song, Kwang. AU - Hsieh, Jer Tsong. AU - Zhao, Dawen. AU - Takahashi, Masaya. AU - Dobin, Timothy. AU - Gandee, Leah. AU - Solberg, Timothy D.. AU - Habib, Amyn A.. AU - Saha, Debabrata. PY - 2013/5/1. Y1 - 2013/5/1. N2 - The purpose of this study was to develop an aggressive locally advanced orthotopic prostate cancer model for assessing high-dose image-guided radiation therapy combined with biological agents. For this study, we used a modified human prostate cancer (PCa) cell line, PC3, in which we knocked down a tumor suppressor protein, DAB2IP (PC3 KD). These prostate cancer cells were implanted into the prostate of nude or Copenhagen rats using either open surgical implantation or a minimally invasive procedure under ultrasound guidance. We report that: i) these DAB2IP-deficient PCa cells form a single focus of ...
Medical professionals consider the prognosis for early stage prostate cancer very good, with a relative 5-year survival rate of 100 percent, as of 2015, states the American Cancer Society....
Background: Few previous studies of metabolic aberrations and prostate cancer risk have taken into account the fact that men with metabolic aberrations have an increased risk of death from causes other than prostate cancer. The aim of this study was to calculate, in a real-life scenario, the risk of prostate cancer diagnosis, prostate cancer death, and death from other causes.. Methods: In the Metabolic Syndrome and Cancer Project, prospective data on body mass index, blood pressure, glucose, cholesterol, and triglycerides were collected from 285,040 men. Risks of prostate cancer diagnosis, prostate cancer death, and death from other causes were calculated by use of competing risk analysis for men with normal (bottom 84%) and high (top 16%) levels of each factor, and a composite score.. Results: During a mean follow-up period of 12 years, 5,893 men were diagnosed with prostate cancer, 1,013 died of prostate cancer, and 26,328 died of other causes. After 1996, when prostate-specific antigen ...
Purpose: We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment.
A Rac1-Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
At the 2019 American Society of Clinical Oncology (ACSO) Annual Meeting, results presented by two PCF-funded investigators from pivotal phase 3 clinical trials will likely lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC). mHSPC refers to men whose prostate cancer has spread to areas of the body outside of the prostate itself, and who are responsive to testosterone-lowering agents. This may refer to men who have had prior surgery or radiation and recurred, or men who were initially diagnosed with disease that was already metastatic (outside the prostate). Patients who are "hormone-sensitive" (aka, "castration-sensitive") may have previously received androgen deprivation therapy (ADT) for a certain amount of time, but their cancer has not yet developed resistance to ADT. Until 2015, the standard-of-care treatment for men with mHSPC was ADT alone. ADT is a class of treatments that block the production or activity ...
Prostate cancer survival rate without treatment - Survival rates for prostate cancer - Survival rates tell what level of individuals with a similar sort and phase of cancer are as yet alive a specific timeframe (ordinarily 5 years) after they have been analyzed.
Prostate cancer is rare in men younger than 50 years of age. The chance of developing prostate cancer increases as men get older.. Family history of prostate cancer. A man whose father, brother, or son has had prostate cancer has a higher-than-average risk of prostate cancer.. Race. Prostate cancer occurs more often in African-American men than in white men. African-American men with prostate cancer are more likely to die from the disease than white men with prostate cancer.. Hormones. The prostate needs male hormones to work the way it should. The main male sex hormone is testosterone. Testosterone helps the body develop and maintain male sex characteristics.. Testosterone is changed into dihydrotestosterone (DHT) by an enzyme in the body.. DHT is important for normal prostate growth but can also cause the prostate to get bigger and may play a part in the development of prostate cancer.. Vitamin E. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) found that vitamin E taken alone ...
The bone metastasis-derived PC3 and the lymph node metastasis-derived LNCaP prostate cancer cell lines are widely studied, having been described in thousands of publications over the last four decades. Here, we report short-read whole-genome sequencing and de novo assembly of PC3 (ATCC CRL-1435) and LNCaP (clone FGC; ATCC CRL-1740) at ~70X coverage. A known homozygous mutation in TP53 and homozygous loss of PTEN were robustly identified in the PC3 cell line, whereas the LNCaP cell line exhibited a larger number of putative inactivating somatic point and indel mutations (and in particular loss of stop codon events). This study also provides preliminary evidence that loss of one or both copies of the tumour suppressor Capicua (CIC) contributes to primary tumour relapse and metastatic progression; potentially offering a treatment target for castration-resistant prostate cancer. Our work provides a resource for genetic, genomic, and biological studies employing two commonly-used prostate cancer cell ...
Background: The consistent finding of a genetic susceptibility to prostate cancer suggests that there are germline sequence variants predisposing individuals to this disease. These variants could be useful in screening and treatment. Methods: We performed an exploratory genome-wide association scan in 498 men with aggressive prostate cancer and 494 control subjects selected from a population-based case-control study in Sweden. We combined the results of this scan with those for aggressive prostate cancer from the publicly available Cancer Genetic Markers of Susceptibility (CGEMS) Study. Single-nucleotide polymorphisms (SNPs) that showed statistically significant associations with the risk of aggressive prostate cancer based on two-sided allele tests were tested for their association with aggressive prostate cancer in two independent study populations composed of individuals of European or African American descent using one-sided tests and the genetic model (dominant or additive) associated with ...
Background and Objectives In previous studies, obesity (measured according to the body mass index) has correlated inconsistently with the risk of biopsy-measured prostate cancer, and specifically high-grade prostate cancer. This meta-analysis aimed to clarify these correlations. Methods A comprehensive literature search of the MEDLINE and EMBASE databases was conducted for relevant studies published through January 2014. The pooled estimates of odds ratios (OR) and confidence intervals (CI) were computed, and the meta-analysis was performed with the STATA software according to a random effects approach. Results A total of 11 studies that included 29,464 individuals were identified. A 5-kg/m2 increase in body mass index was associated with a 15% (OR, 1.15; 95% CI, 0.98-1.34) higher risk of prostate cancer detection and a 37% (OR, 1.37; 95% CI, 1.19-1.57) higher risk of high-grade prostate cancer detection at biopsy. There were no differences among the results of studies conducted in the USA, Europe or
Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKL-independent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular ...
One can say that prostate cancer survival rates look positive. By the time men are diagnosed with prostate cancer, they are around the age of 70. Many of these men face death due to other complications of health problems over the period of 5 years that is irrelevant to prostate cancer. When survival rate of prostate cancer is calculated excluding these group of men who die of other causes, the figures look very encouraging. About 99% of men with prostate cancer that is common will hold out for 5 years and more upon being diagnosed. And for most of the men whose prostate cancer has not spreaded and remain only in one area nearby, the prognosis is far more promising. Close to all of them will live for a minimum of 5 years. For men with prostate cancer that has spreaded which make up about 30%, 1 in 3 of them will live for at least 5 years after diagnosis. However, this is mere approximate statistic.. It is quite complex to understand the prognosis of your prostate cancer because of the various ...
Neurotensin is a neuroendocrine peptide acting as a trophic factor in a variety of cells in vivo but it can also function as an autocrine growth factor in human prostate cancer cells in vitro. In addition, the high-affinity G protein-coupled NT receptor (NTS1) is overexpressed in prostate cancer cell lines. Increasing evidence argues for a direct correlation between specific alternative splice variants and cancer. We detected four splice variants of the NTS1 receptor in human prostate cancer cell lines. These isoforms include one or more exons skipping as well as an alternative 5 splice donor site and are expressed in the late-stage androgen independent prostate cancer cell lines PC3 and DU145, but not in the early-stage androgen-sensitive LNCaP or in normal prostate tissue, which only express the normal transcript ...
Intermittent administration of Taxotere® (docetaxel) appears to provide as much benefit, with fewer side effects, than continuous administration of Taxotere among patients with hormone-refractory prostate cancer. These results were recently presented at the 23rd annual meeting of the European Association of Urology.. Prostate cancer is one of the most common types of cancer diagnosed in men in the United States. One frequent approach to treatment of prostate cancer is androgen deprivation therapy (ADT), also referred to as hormone therapy. Prostate cancer is stimulated to grow from exposure to the circulating male hormone testosterone. ADT reduces the production of testosterone in the male body, reducing its growth stimulatory effects on cancer cells.. Unfortunately, prostate cancer cells can become resistant to the effects of hormone therapy, a condition referred to as hormone refractory prostate cancer (HRPC) or androgen-independent prostate cancer (AIPC). Men with AIPC are often treated with ...
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a custom Illumina array (iCOGS) in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium. Twenty-three new prostate cancer susceptibility loci were identified at genome-wide significance (P | 5 × 10(-8)). More than 70 prostate cancer susceptibility loci, explaining ∼30% of the familial risk for this disease, have now been identified. On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies.
Read more about how low risk prostate cancer patients experience continued good health related quality of life under monitored watchful waiting approach.
The Scottish Medicines Consortium (SMC) has accepted Sanofi Genzymes Jevtana (cabazitaxel) for routine use in NHS Scotland to treat metastatic hormone-refractory prostate cancer (mHRPC).. Jevtana (cabazitaxel) is a chemotherapy option available on the NHS for advanced prostate cancer that is not responsive to hormone therapies, following initial chemotherapy (docetaxel).. The decision reduces potential disparities in care across the UK for this vulnerable group of patients.. Sanofi Genzyme UK & Ireland Oncology and Immunology franchise director Dr Jasmin Hussein said: "Through ongoing collaboration our treatment can now be accessed by all doctors who treat patients with metastatic hormone-refractory prostate cancer in the country.. "The approval of Jevtana by the SMC is important, as it represents a new treatment choice where limited options have existed.". Nearly one in two men in Scotland will be affected by some form of prostate disease at some stage of their lives and about one in 11 men ...
An NCI Cancer Currents blog post on results from two clinical trials that showed adding abiraterone to androgen-deprivation therapy improved survival for men with metastatic hormone-sensitive prostate cancer.
Figure 3 Deletion of the tumor suppressor Capicua (CIC) in prostate cancer (A) Genome browser display showing a CNV0 event (red dotted line) on chromosome 19 that spans CIC, PAFAH1B3, PRR19, and TMEM145 in the PC3 prostate cancer cell line. (B) Plot of putative chromosomal loss spanning the four-gene region in LNCaP (left panel) and PC3 (right panel). The x-axis represents the genomic position and the y-axis the number of normalized counts. (C) Loss of the chromosome 19 region encompassing CIC, PAFAH1B3, PRR19, and TMEM145 in the Prostate FHCRC 2016 cBioPortal data set. Individual tumor samples are shown in columns and genes in rows. (D) CIC copy number alterations in primary and metastatic prostate cancer samples from eight clinical data sets interrogated using cBioPortal. (E) Disease-free survival in primary prostate cancer patients with loss of a single CIC gene copy (n = 13 relapse events) is significantly decreased compared to those without any CIC deletion events. The Prostate (MSKCC ...
Background. Insulin-like growth factors (IGFs) have mitogenic and anti-apoptotic effects on prostate epithelial cells. Through modulation of IGF bioactivity, IGF binding proteins (IGFBPs) also have growth regulatory effects on prostate cells. Operating through the vitamin D receptor (VDR), vitamin D shows strong inhibitory effects on prostate cancer growth in both laboratory and human studies. Recent evidence indicates that vitamin D-induced prostate cancer inhibition is accompanied by increased IGFBP expression, suggesting that the vitamin D and IGF regulatory systems may operate together to affect prostate cancer. Methods. We sought to examine whether VDR gene polymorphisms affect prostate cancer risk -either independently or with plasma IGF or IGFBP levels - in a population-based case-control study in Shanghai, China. Histologically-confirmed cases of primary prostate cancer newly diagnosed between 1993 and 1995 (N = 191) and randomly selected age-matched population controls (N = 304) ...
This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients. Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of
TY - JOUR. T1 - Prostate cancer gene therapy and the role of radiation. AU - Kaminski, J. M.. AU - Nguyen, K.. AU - Buyyounouski, M.. AU - Pollack, A.. PY - 2002/1/1. Y1 - 2002/1/1. N2 - Even though prostate cancer is detected earlier than in the pre-PSA era, prostate cancer is the second leading cause of cancer mortality in the American male. Prostate cancer therapy is not ideal, especially for high-risk localized and metastatic cancer; therefore, investigators have sought new therapeutic modalities such as angiogenesis inhibitors, inhibitors of the cell signaling pathway, vaccines, and gene therapy. Gene therapy has emerged as potential therapy for both localized and systemic prostate cancer. Gene therapy has been shown to work supra-additively with radiation in controlling prostate cancer in vivo. With further technological advances in radiation therapy, gene therapy, and the understanding of prostate cancer biology, gene therapy will potentially have an important role in prostate cancer ...
Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients with hormone refractory prostate cancer (HRPC), and has become the standard of care. The beneficial effects of any therapy in HRPC may be diverse and include reduction in tumor bulk (when measurable), reduction in prostate-specific antigen PSA, reduction in symptoms (particularly pain), or stabilization of disease. Clear reductions in tumor bulk or PSA may provide objective evidence of a treatment effect, and stabilization of disease may be just as clinically meaningful in patients who are actively progressing prior to starting therapy. Pemetrexed has shown a broad array of activity in many diseases that until now were thought to be non-responsive to chemotherapy in the second-line setting.. This trial is designed to further assess the efficacy, safety, tolerability, and pharmacogenetics of pemetrexed as a single agent in subjects with HRPC whose disease has progressed following one prior taxane-based ...
TY - JOUR. T1 - PAC1-R null isoform expression in human prostate cancer tissue. AU - Mammi, Caterina. AU - Frajese, Giovanni V.. AU - Vespasiani, Giuseppe. AU - Mariani, Stefania. AU - Gnessi, Lucio. AU - Farini, Donatella. AU - Fabbri, Andrea. AU - Frajese, Gaetano. AU - Moretti, Costanzo. PY - 2006/4/1. Y1 - 2006/4/1. N2 - BACKGROUND. PACAP is a member of the VIP/GHRH family of neuropeptides and has important effects on prostate cell proliferation. Here we analyze the expression and localization of PACAP and its specific receptor variants (PAC1-R) in tissues collected from patients undergoing prostate biopsy and surgery for benign prostatic hyperplasia (BPH) and prostate cancer (PCa). METHODS. Reverse transcriptase (RT)-polymerase chain reaction (PCR), DNA sequencing, and immunohistochemistry. RESULTS. PACAP and PAC1-R were localized by immunohistochemistry in the prostate tissue. While in healthy and BPH tissues PAC1-R positive staining is present in all the epithelial cells lining the lumen ...
The low molecular weight thiol (-SH) content of a human prostate carcinoma cell line (LNCap), important to the cellular resistance to drugs and irradiation, was investigated using three forms of thiol assay each utilizing different chemistries. The composition of the mixture was examined by derivatization of the thiols with a three-fold excess of the Ellman reagent to give mixed aromatic disulfides. The components were isolated by chromatography on C18 reverse phase silica gel followed by DE52 anion exchange separation, and then analyzed by capillary electrophoresis against prepared standards. The glutathione adduct (GSSE) and an unknown disulfide (RSSE) were the major components isolated on DE52 together with two minor ones. However, from the absorbance at 325 nm, it was found that the GSSE isolated (1.5 ± 0.2 femtomoles/cell) could only account for 28.5 ± 4.3% of the total ASF thiols. It appeared that the bulk of the thiol material had not formed a stable mixed disulfide with Ellmans reagent, and
Validation Study Data Published in The Journal of Urology. MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDxfor Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi:10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.. One of the most significant challenges in diagnosing early stage PCa is proper staging and grading of the patients in order to choose the best treatment plan. Current methods such as clinical staging, PSA serum level and biopsy ...
Men with metastatic castrate-resistant prostate cancer can experience an array of treatment-related side effects. Accumulating evidence suggests exercise may alleviate some of these adversities and assist in disease management. However, empirical evidence in advanced prostate cancer patients remains limited. The purpose of this study is to determine whether men with metastatic prostate cancer, who are ineligible for high-intensity exercise, can partake in a home-based, moderate-intensity exercise program and the impact of doing so on quality of life and physical fitness parameters. Thirty men with adenocarcinoma of the prostate and progressive systemic, metastatic disease will be recruited. Clinicians will screen patients against inclusion criteria to determine eligibility. All men enrolled will be prescribed a tailored, home-based, moderate-intensity exercise intervention consisting of aerobic and strengthening components for 12 weeks. Patients will receive supplementary education materials and weekly
BACKGROUND:Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity. METHODS:In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early-stage PCa and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T-cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate-specific antigen (PSA) change, and assessment of
Prostate cancer is the most frequently diagnosed cancer among men in the western world. The androgen receptor, a phosphoprotein, is suspected to be involved in all stages of the prostate cancer. Androgen receptor activity can be modulated by various kinases such as PKA, MAPK, AKT, and Src. Phosphorylation is an important post-translational modification and serves as a molecular on-off switch to regulate signaling. Disruptions of cellular phosphorylation are associated with various diseases such as cancer and kinases provide important drug targets. Here we present an analysis of the phosphoproteome in LNCaP human prostate cancer cells. The analytical strategy employed here used proteomics based methodologies with a combination of detergents and chaotropic reagents during trypsin digestion followed by titanium dioxide enrichment of phosphopeptides. Over the course of multiple analyses by mass spectrometry we identified a total of 746 phosphorylation sites in 540 phosphopeptides corresponding to 116
A new drug has improved overall survival among patients with hormone resistant prostate cancer. The endothelin A antagonist ZD4054 was investigated in a placebo-controlled trial among 300 patients whose hormone-resistant prostate cancer had metastasized to bone ...
Adenocarcinoma of the prostate is the most prevalent tumor in men, a major cause of morbidity and mortality mainly because of the hormone refractory component. Hormone refractory prostate cancer...
Volunteer with Prostate Cancer Research Institute. Find Prostate Cancer Research Institute volunteering opportunities at VolunteerMatch!
Study design A phase I/II clinical trial in patients with hormone refractory metastatic prostate cancer.. Primary objective phase I component of study:. To determine a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer.. Primary objective phase II component of study:. To determine the therapeutic efficacy of combined therapy of azacitidine, docetaxel, and prednisone, in the treatment of hormone refractory metastatic prostate cancer. The primary measure of therapeutic efficacy is response, defined as prostate-specific antigen (PSA) response, complete response (CR), or partial response (PR).. Secondary endpoints are toxicity, duration of response, progression-free survival, and overall survival. ...
NIEHS Grants P30ES006096, U01ES019480, U01ES020988. In an NIEHS-supported study, researchers found that men with prostate cancer had higher urinary levels of bisphenol A (BPA), suggesting that urinary BPA level is an independent prognostic marker of prostate cancer. The investigators also report new information about a possible mechanism for how BPA affects prostate cells to transform them into cancer cells.. The researchers examined urine BPA levels in 60 urology patients and found that prostate cancer patients had higher levels of BPA, 5.74 microgram per gram (ug/g), [95 percent confidence interval (CI); 2.63, 12.51]) than patients without prostate cancer, 1.43 ug/g [95 percent CI; 0.70, 2.88]) (p = 0.012). The difference in BPA levels was even more significant in prostate cancer patients who were older than 65.. They also examined how prostate cancer and normal prostate cell lines responded to low doses of BPA. For both types of cells, BPA exposure increased the percentage of cells with more ...
1 alpha,25-Dihydroxyvitamin D (1,25 D; also know as calcitriol), the hormonal form of vitamin D, can inhibit the proliferation and promote the differentiation of human prostate adenocarcinoma cells. However, little is known about the effects of 1,25 D on the invasive ability of prostate cancer cells. We used an in vitro bioassay of cell invasion (Amgel assay) to examine the effects of 1,25 D and a "noncalcemic" vitamin D analogue, 1,25-dihydroxy-16-ene-23-yne-cholecalciferol (16-23-D3), on the invasiveness of three well-characterized human prostate carcinoma cell lines: DU 145, PC-3, and LNCaP. PC-3 and LNCaP cells were poorly invasive in Amgel and were hardly affected by treatment with 1,25 D or 16-23-D3 (, 3%). Conversely, DU 145 cells were highly invasive in Amgel, and their invasion was markedly inhibited by 1,25 D and 16-23-D3 (maximally 66 and 59.4% respectively). This effect was both dose-dependent, with maximal inhibition at 1 x 10(-7) M and 72 h. Significant inhibition of invasion was ...
TY - JOUR. T1 - Cigarette smoking and prostate cancer mortality in four US States, 1999-2010. AU - Jones, Miranda. AU - Joshu, Corinne E.. AU - Kanarek, Norma F. AU - Navas Acien, Ana. AU - Richardson, Kelly A.. AU - Platz, Elizabeth A. PY - 2016/4/1. Y1 - 2016/4/1. N2 - Introduction In the United States, prostate cancer mortality rates have declined in recent decades. Cigarette smoking, a risk factor for prostate cancer death, has also declined. It is unknown whether declines in smoking prevalence produced detectable declines in prostate cancer mortality. We examined state prostate cancer mortality rates in relation to changes in cigarette smoking. Methods We studied men aged 35 years or older from California, Kentucky, Maryland, and Utah. Data on state smoking prevalence were obtained from the Behavioral Risk Factor Surveillance System. Mortality rates for prostate cancer and external causes (control condition) were obtained from the Centers for Disease Control and Preventions Wide-Ranging ...
The Company has conducted two Phase 2 trials of GVAX(R) vaccine for prostate cancer in patients with hormone refractory metastatic prostate cancer. At the May 2005 American Society for Clinical Oncology (ASCO) meeting, the company reported updated results from its second trial which indicated that in 22 patients receiving a dosing regimen comparable to that being used in Phase 3, the median survival has not yet been reached and will meet or exceed 24.1 months based on the median follow-up time in these patients. In September 2002, the company reported final results from its earlier trial of the vaccine in hormone refractory metastatic prostate cancer in which a median survival of 26.2 months was observed in 34 patients receiving vaccine treatment. These results compare favorably to the median survival of 18.9 months for hormone-refractory metastatic prostate cancer patients who were treated with Taxotere(R) plus prednisone based on a recently reported multi-center Phase 3 trial ...
The Prostate Cancer Research Institute helps men and caregivers research their prostate cancer treatment options. Enable men and their caregivers to partner with their medical professional to maximize survival and quality of life.
In the current study, we examine the effects of an agent traditionally considered as an antioxidant on prostate carcinoma cells. Epidemiological studies provide intriguing evidence that antioxidant dietary factors such as β-lycopene and vitamin E may help prevent prostate cancer development (5). Although these agents have been classified as antioxidants, the mechanism by which they may contribute to prostate cancer prevention has not been firmly established. Androgens are known to have an essential role in prostate cancer development (3). Modulation of androgen activity may provide a means of prostate cancer prevention (26). Here, we report the antioxidant moiety of vitamin E, PMCol, to be a potent antiandrogen in androgen-sensitive human prostate carcinoma cells.. The LNCaP human prostate carcinoma cell line is one of the few prostate cell lines that show demonstrable physiological changes resulting from androgen exposure, such as growth modulation (9). Therefore, the LNCaP cell line has ...
Accumulated evidence shows that many cancers including prostate cancer disseminate to metastatic sites early in the natural history of disease and can remain undetected and quiescent for extended periods of time.3, 4, 10 In one recent report, disseminated prostate cancer cells (DTCs) can be detected in the bone marrow of 57% men who are without evidence of disease after prostatectomy. With a median follow-up of 42 months, 52% of those with DTCs have not recurred, including patients who still have DTCs 12 years after surgery.5 Thus, in the context of prostate cancer recurrence, metastatic colonization, or the progressive outgrowth of disseminated cancer cells within a secondary site into clinically manifested metastases, is a particularly critical aspect to the multistep metastatic process.7, 35 The molecular factors that control the survival and eventual growth of these disseminated cells are largely unknown.. Experimental modulation of metastasis suppressor genes preclinically affords the ...
Protein tyrosine kinase 7 (PTK7) has been studied in various tumors, but its role in prostate cancer remains unknown. This study is aimed to investigate the prognostic and predictive significance of PTK7 in patients with prostate cancer. PTK7 expression was evaluated by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis in 20 pairs of benign prostatic hyperplasia specimens and prostate cancer specimens. Then, we examined the immunohistochemical expression of PTK7 in 180 prostate cancer specimens and evaluated its clinical significances. Elevated PTK7 expression was significantly associated with lymph node metastases, seminal vesicle invasion, prostate cancer stage, the higher preoperative prostate-specific antigen, the higher Gleason score, angiolymphatic invasion, and biochemical recurrence. The results revealed that the overexpression of PTK7 in prostate cancer was an independent prognostic factor for poor overall survival and biochemical recurrence-free
In this prospective cohort study, we found that men with sleep disruption were at increased risk of prostate cancer, particularly advanced prostate cancer, when compared with men who did not report any sleep problems.. The association between sleep disruption and prostate cancer was stronger for advanced disease than for overall prostate cancer. This may be a chance finding due to limited number of cases in the analyses for advanced cases. It is also possible that underlying mechanisms of sleep disturbance, such as circadian disruption and reduced melatonin levels, affect prostate cancer progression to a greater extent than prostate cancer initiation (19). Nonetheless, our data support the hypothesis that some aspect related to sleep disruption may confer an increased risk of prostate cancer.. Most epidemiologic studies to date on the effect of sleep or circadian rhythm disruption have focused on the impact of shift work on cancer risk. Consistent with the hypotheses for sleep disruption, 4 ...
Prostate-specific antigen (PSA) testing has caused a steep increase in the incidence of prostate cancer, especially the incidence of localised low risk disease. In order to decrease the overdiagnosis accompanied by PSA testing, analysis of inherited genetic variants have been suggested as potential tools for clinical assessment of disease risk. With the aim of minimizing overtreatment and postpone side-effects of curative treatment for low risk prostate cancer, active surveillance, a treatment strategy with initial surveillance and deferred radical prostatectomy at the time of progression has evolved. The aim of this thesis was to study the validity of PSA (paper I) and inherited genetic variants (paper II) for early diagnosis of prostate cancer, to assess the extent of PSA testing in Sweden (paper III), and to study the safety of deferred radical prostatectomy in localised low to intermediate risk prostate cancer (paper IV).. The study designs were i) case-control studies nested within the ...
HealthDay News) -- Because testosterone can help prostate tumors grow, men with prostate cancer are often given hormone-suppressing treatment.. But new research suggests that delivering the treatment in prostate cancers early stages may, in turn, hike a mans odds for another illness -- heart failure.. The treatment in question is known as androgen-deprivation therapy.. The take-home message from the new study is that patients with localized prostate cancer should be followed to minimize the health effects of androgen-deprivation therapy on the cardiovascular system, said study author Reina Haque. Shes a researcher with the Kaiser Permanente Southern California Department of Research & Evaluation.. Haques advice? Patients should consider [heart-healthy] lifestyle changes, and physicians should actively monitor the patients health for early signs of heart disease, she said in a Kaiser Permanente news release.. A prostate cancer expert who reviewed the study agreed.. This new data is ...
The Prostate Cancer Pathology Resource Network Award was established in 2009 to provide support for the development of a prostate cancer biorepository consortium that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens through a collaborative network across multiple institutions. The award is designed to support a biorepository that will enable the prostate cancer research community to address multiple areas of research such as biomarkers, therapy, genetics, and tumor biology to move toward the PCRP vision of conquering prostate cancer. FY13 Prostate Cancer Pathology Resource Network Awards. ...
The significance of apoptosis in relation to the development and progression of prostate cancer remains largely undefined, bcl-2 is an oncogene that functions by overriding apoptosis. bcl-2 expression was localized to the basal epithelial cells in the normal human prostate with the use of immunohistochemistry. Androgen-dependent and androgen-independent prostate carcinomas were evaluated immunohistochemically for bcl-2 expression, bcl-2 was undetectable in 13 of 19 cases of androgen-dependent cancers. In contrast, androgen-independent cancers displayed diffuse, high levels of bcl-2 staining (P , 0.01). In rats, steady-state levels of bcl-2 mRNA, assessed by S1 assays, reached maximum levels 10 days following castration. Addition of exogenous testosterone with, or without, flutamide demonstrated that the increased bcl-2 mRNA resulted from androgen ablation. Our findings indicate that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate ...